Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome

NCT06518005 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Crigler-Najjar Syndrome

Interventions

DRUG: Imlifidase
DRUG: GNT0003

Sponsor

Genethon

Collaborators

[object Object]